Tamiflu (generic name: Oseltamivir) a common antiviral drug used in the treatment and prophylaxis of both Influenza virus A and Influenza virus B, will be marketed in a generic form in India. It is a prodrug, which is hydrolysed hepatically to the active metabolite, the free carboxylate of oseltamivir. It was developed by Gilead Sciences and is currently marketed by Hoffmann-La Roche (Roche) under the trade name Tamiflu.
Cipla received marketing approval from the drug controller-general of India and will launch a generic version of  Oseltamivir, Anti-Flu, in the domestic market this month. The drug will be priced at about Rs 1,000 per strip of 10  75 mg tablets, which is less than half the current Tamiflu market price of $60. The required dosage is two tablets every day during five days.
Share this: 






This page is archived, and is no longer publicly editable.
Got a correction? Add the template {{editprotected}} to the talk page along with your corrections, and it will be brought to the attention of the administrators.
Please note that due to our archival policy, we will not alter or update the content of articles that are archived, but will only accept requests to make grammatical and formatting corrections.
Note that some listed sources or external links may no longer be available online due to age.
Got a correction? Add the template {{editprotected}} to the talk page along with your corrections, and it will be brought to the attention of the administrators.
Please note that due to our archival policy, we will not alter or update the content of articles that are archived, but will only accept requests to make grammatical and formatting corrections.
Generic Tamiflu in India